FI3117216T3 - Menetelmä kiinteäkasvaimisen syövän tunnistamiseksi - Google Patents

Menetelmä kiinteäkasvaimisen syövän tunnistamiseksi Download PDF

Info

Publication number
FI3117216T3
FI3117216T3 FIEP15716168.8T FI15716168T FI3117216T3 FI 3117216 T3 FI3117216 T3 FI 3117216T3 FI 15716168 T FI15716168 T FI 15716168T FI 3117216 T3 FI3117216 T3 FI 3117216T3
Authority
FI
Finland
Prior art keywords
solid tumor
psa
time point
tumor cancer
biomarker
Prior art date
Application number
FIEP15716168.8T
Other languages
English (en)
Finnish (fi)
Inventor
Henrik Grönberg
Original Assignee
Phadia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phadia Ab filed Critical Phadia Ab
Application granted granted Critical
Publication of FI3117216T3 publication Critical patent/FI3117216T3/fi

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57565—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen [CEA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FIEP15716168.8T 2014-03-11 2015-03-11 Menetelmä kiinteäkasvaimisen syövän tunnistamiseksi FI3117216T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1450274 2014-03-11
SE1450420 2014-04-04
PCT/SE2015/050272 WO2015137870A1 (en) 2014-03-11 2015-03-11 Method for detecting a solid tumor cancer

Publications (1)

Publication Number Publication Date
FI3117216T3 true FI3117216T3 (fi) 2023-04-27

Family

ID=52829276

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP15716168.8T FI3117216T3 (fi) 2014-03-11 2015-03-11 Menetelmä kiinteäkasvaimisen syövän tunnistamiseksi

Country Status (9)

Country Link
US (1) US10451626B2 (enExample)
EP (2) EP4220170A3 (enExample)
JP (1) JP6625061B2 (enExample)
AU (2) AU2015230017B2 (enExample)
CA (2) CA3134289A1 (enExample)
DK (1) DK3117216T3 (enExample)
FI (1) FI3117216T3 (enExample)
RU (1) RU2720148C9 (enExample)
WO (1) WO2015137870A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3312749T3 (fi) 2012-03-05 2024-05-31 Oy Arctic Partners Ab Menetelmiä ja laitteita eturauhassyövän riskin ja eturauhasen tilavuuden ennustamiseen
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
MY192513A (en) 2014-03-28 2022-08-24 Opko Diagnostics Llc Compositions and methods related to diagnosis of prostate cancer
WO2016160545A1 (en) 2015-03-27 2016-10-06 Opko Diagnostics, Llc Prostate antigen standards and uses thereof
EP3430170B1 (en) 2016-03-16 2023-08-16 Dana-Farber Cancer Institute, Inc. Methods for genome characterization
DK3270163T3 (en) * 2016-07-15 2018-11-19 Proteomedix Ag PROCEDURE FOR DETECTING PROTEINS IN HUMAN SAMPLES AND APPLICATIONS OF SUCH PROCEDURES
WO2018141828A1 (en) * 2017-02-01 2018-08-09 Phadia Ab Method for indicating a presence or non-presence of prostate cancer in individuals with particular characteristics
US20210333265A1 (en) * 2017-02-03 2021-10-28 The Johns Hopkins University Mini-cancers utilization for personalized cancer drug regimens
RU2664706C2 (ru) * 2017-06-02 2018-08-21 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский радиологический центр" Министерства здравоохранения Российской Федерации (ФГБУ "НМИРЦ" Минздрава России) Способ прогнозирования клинического статуса рака предстательной железы
JP7127422B2 (ja) * 2017-08-30 2022-08-30 東ソー株式会社 癌を検出する方法及び検出試薬
WO2020205204A1 (en) * 2019-04-03 2020-10-08 Opko Diagnostics, Llc Methods for the detection of prostate cancer
IT202000029948A1 (it) * 2020-12-04 2022-06-04 Nib Biotec S R L Metodo per la diagnosi di tumore alla prostata in pazienti in differente fascia di età
KR20250107193A (ko) * 2022-10-27 2025-07-11 마이옴, 인크. 다수의 데이터 소스들을 조합하여 질병들의 조기 검출을 하기 위한 접근법
WO2024092136A2 (en) * 2022-10-28 2024-05-02 Memorial Sloan-Kettering Cancer Center Machine learning modeling for inpatient prediction

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030219840A1 (en) 2002-05-24 2003-11-27 Mikolajczyk Stephen D. Method of analyzing proenzyme forms of prostate specific antigen in serum to improve prostate cancer detection
US20050277137A1 (en) 2003-08-15 2005-12-15 University Of Pittsburgh Diagnostic multimarker serological profiling
KR100830811B1 (ko) 2006-09-18 2008-05-20 충북대학교 산학협력단 종양표시인자 검출용 바이오센서
FR2934698B1 (fr) 2008-08-01 2011-11-18 Commissariat Energie Atomique Procede de prediction pour le pronostic ou le diagnostic ou la reponse therapeutique d'une maladie et notamment du cancer de la prostate et dispositif permettant la mise en oeuvre du procede.
WO2010081240A1 (en) 2009-01-19 2010-07-22 Miraculins Inc. Diagnostic assays for prostate cancer using psp94 and psa biomarkers
US20120121618A1 (en) 2009-02-12 2012-05-17 Dana-Farber Cancer Institute, Inc. Predicting And Treating Prostate Cancer
EP2407555A1 (en) 2010-07-14 2012-01-18 Fundació Institut de Recerca Hospital Universitari Vall d'Hebron, Fundació Privada Methods and kits for the diagnosis of prostate cancer
US9732389B2 (en) 2010-09-03 2017-08-15 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
US20120202888A1 (en) 2010-10-08 2012-08-09 The Brigham And Women's Hospital, Inc. Biomarkers of prostate cancer and predicting mortality
US20120150032A1 (en) 2010-12-13 2012-06-14 Julius Gudmundsson Sequence Variants Associated with Prostate Specific Antigen Levels
US20150024952A1 (en) 2010-12-28 2015-01-22 Arlet Alarcon Molecular profiling for cancer
CA2799163C (en) 2011-12-18 2025-01-07 20/20 Genesystems, Inc. Methods and algorithms for aiding in the detection of cancer
JP2015524052A (ja) 2012-05-16 2015-08-20 ファディア・アクチボラゲットＰｈａｄｉａ ＡＢ 前立腺癌の存在または不存在の提示方法
CA2891394C (en) * 2012-11-20 2023-03-14 Phadia Ab Prognostic method for individuals with prostate cancer
JP2016503301A (ja) 2012-11-20 2016-02-04 ファディア・アクチボラゲットＰｈａｄｉａ ＡＢ 侵攻性前立腺癌の存在または不存在を判定する方法

Also Published As

Publication number Publication date
AU2015230017B2 (en) 2021-06-17
AU2021232712B2 (en) 2024-10-03
EP4220170A2 (en) 2023-08-02
RU2720148C9 (ru) 2020-09-28
HK1231559A1 (en) 2017-12-22
CA3134289A1 (en) 2015-09-17
AU2021232712A1 (en) 2021-10-14
CA2940445C (en) 2021-11-30
RU2016139491A (ru) 2018-04-16
US20170108501A1 (en) 2017-04-20
JP2017508970A (ja) 2017-03-30
AU2015230017A1 (en) 2016-09-08
EP3117216B1 (en) 2023-01-11
WO2015137870A1 (en) 2015-09-17
DK3117216T3 (da) 2023-04-03
RU2720148C2 (ru) 2020-04-24
EP4220170A3 (en) 2023-12-13
JP6625061B2 (ja) 2019-12-25
US10451626B2 (en) 2019-10-22
CA2940445A1 (en) 2015-09-17
EP3117216A1 (en) 2017-01-18
RU2016139491A3 (enExample) 2018-10-15

Similar Documents

Publication Publication Date Title
FI3117216T3 (fi) Menetelmä kiinteäkasvaimisen syövän tunnistamiseksi
Chen et al. Biomarkers for prostate cancer: from diagnosis to treatment
Bhawal et al. Challenges and opportunities in clinical applications of blood-based proteomics in cancer
Ferrari et al. Towards novel non-invasive colorectal cancer screening methods: a comprehensive review
Gai et al. Epigenetic biomarkers in cell-free DNA and applications in liquid biopsy
Zavridou et al. Prognostic significance of gene expression and DNA methylation markers in circulating tumor cells and paired plasma derived exosomes in metastatic castration resistant prostate cancer
JP2017508970A5 (enExample)
Kudela et al. Breast cancer in young women: status quo and advanced disease management by a predictive, preventive, and personalized approach
Martínez-Montiel et al. Alternative splicing in breast cancer and the potential development of therapeutic tools
Busby et al. The complex subtype-dependent role of connexin 43 (GJA1) in breast cancer
Spans et al. The genomic landscape of prostate cancer
Jaworski et al. Circulating cell-free tumour DNA for early detection of pancreatic cancer
JP2016508026A5 (enExample)
MX2018011725A (es) Metodo para emplear expresion genica para determinar pronostico de cancer de prostata.
Keup et al. Combinatorial power of cfDNA, CTCs and EVs in oncology
Verma et al. Biomarkers in prostate cancer epidemiology
Adinew et al. The prognostic and therapeutic implications of the chemoresistance gene BIRC5 in triple-negative breast cancer
JP2016521979A5 (enExample)
Grizzi et al. Circulating tumor DNA in gastric adenocarcinoma: future clinical applications and perspectives
Ravegnini et al. Simultaneous analysis of SEPT9 promoter methylation status, micronuclei frequency, and folate-related gene polymorphisms: The potential for a novel blood-based colorectal cancer biomarker
Yu et al. Functional genomic analysis of breast cancer metastasis: implications for diagnosis and therapy
Jang et al. Proteomics of primary uveal melanoma: insights into metastasis and protein biomarkers
Gao et al. Proteomic tissue-based classifier for early prediction of prostate cancer progression
Wu et al. Identification and validation of the lncRNA MYOSLID as a regulating factor of necroptosis and immune cell infiltration in colorectal cancer following necroptosis-related LncRNA model establishment
Scaglione et al. Homologous recombination deficiency (HRD) scoring, by means of two different shallow whole-genome sequencing pipelines (sWGS), in ovarian cancer patients: a comparison with Myriad MyChoice assay